



Uganda Russia Boston Alcohol Network for  
Alcohol Research Collaboration on HIV/AIDS



EXCEPTIONAL CARE. WITHOUT EXCEPTION.



School of Medicine



Clinical Addiction Research and Education

***September 7, 2016***

# How to Build It: The “Massachusetts Model” of Office Based Opioid Treatment (OBOT) with Buprenorphine

**Jeffrey H. Samet, MD, MA, MPH**

Chief, Section of General Internal Medicine

Boston Medical Center

Professor of Medicine and Community Health Sciences

Boston University Schools of Medicine and Public Health

# A New Law

## Drug Addiction Treatment Act (DATA) 2000

- ❖ Amendment to the Controlled Substances Act
- ❖ Allows physician to prescribe narcotic drugs scheduled III, IV or V, FDA approved for opioid maintenance or detoxification treatment
  - Prior 10/2002 no drug existed
  - Methadone does not qualify

# DATA 2000:

## Physician Qualifications


### Physicians must:

- ❖ Be licensed to practice by his/her state
- ❖ Have the capacity to refer patients for psychosocial treatment
- ❖ Limit number of patients receiving buprenorphine to 30 patients for at least the first year
- ❖ File for a new waiver after first year to increase their limit to 100 patients
- ❖ Be qualified to provide buprenorphine and receive a license waiver
- ❖ Can apply for new waiver; expand to 275 patients if addiction certified and work in medical settings for 24 hour services

# BUPRENORPHINE



# Opioid Potency



# How Does Buprenorphine Work?

- ❖ “Ceiling effect” on opioid effects
- ❖ High affinity for opioid receptor
- ❖ Slow dissociation from opioid receptor
- ❖ Formulated with naloxone
  - Naloxone blocks opiate effect if injected
  - Naloxone is degraded (inert) if taking orally




# Goals of Pharmacotherapy with Buprenorphine:

- ❖ Prevention or reduction of withdrawal symptoms
- ❖ Prevention or reduction of drug craving
- ❖ Prevention of relapse to use of addictive drug
- ❖ Restoration to or toward normalcy of any physiological function disrupted by drug use

# Only 4% of Eligible US Doctors are Certified to Prescribe Buprenorphine

May 2014



1-100:



101-320:



321-560:



561 and over:



# Needs Assessment in Massachusetts

- ❖ High rate of opioid addiction
- ❖ High number of fatal and non-fatal opioid overdoses
- ❖ Long waits for opioid treatment, both methadone and buprenorphine
- ❖ Some people refuse MMT
- ❖ Not enough MA physicians had waivers
- ❖ Some waived physicians were not prescribing

# Buprenorphine in Massachusetts




- ❖ Opioid-related hospitalizations and fatal overdoses increased since mid-1990s
- ❖ Expansion of office-based treatment part of the 2005 state strategic plan
- ❖ 2005 – 1% (356/29,959) physicians waived and many not prescribing
- ❖ Massachusetts Department of Public Health surveyed **all 356 physicians** waived to prescribe buprenorphine

## Office-Based Management of Opioid Dependence with Buprenorphine: Clinical Practices and Barriers

[Alexander Y. Walley, MD, MSc](#),<sup>1,2</sup> [Julie K. Alperen, DrPH](#),<sup>3</sup> [Debbie M. Cheng, ScD](#),<sup>1,4</sup> [Michael Botticelli](#),<sup>2</sup> [Carolyn Castro-Donlan](#),<sup>2</sup> [Jeffrey H. Samet, MD, MA, MPH](#),<sup>1,5</sup> and [Daniel P. Alford, MD, MPH](#)<sup>1</sup>

*J Gen Intern Med. 2008;23:1393-1398.*

# 2005 survey to all waivered physicians (n=356)



# Barriers to Buprenorphine Prescribing

Insufficient nursing support	20 %
Insufficient office support	19 %
Payment issues	17 %
Lack of institutional support	16 %
Insufficient staff knowledge	12 %
Pharmacy issues	8 %
Low demand	7 %
Office staff stigma	5 %
Insufficient physician knowledge	3 %
One or more barriers	55%

# Non-prescribers

- ❖ If barriers improved:
- ❖ 54% (33/61) of never prescribers said that they will prescribe
- ❖ 67% (10/15) of previous prescribers said that they will prescribe





Only physicians can prescribe

\*In the future, NPs will be able to prescribe

However, it takes a Multidisciplinary Team Approach for effective addiction treatment





## **Collaborative Care of Opioid-Addicted Patients in Primary Care Using Buprenorphine Five-Year Experience**

Daniel P. Alford, MD, MPH; Colleen T. LaBelle, RN; Natalie Kretsch, BA; Alexis Bergeron, MPH, LCSW; Michael Winter, MPH; Michael Botticelli, MEd; Jeffrey H. Samet, MD, MA, MPH

*Arch Intern Med.* 2011;171:425-431.

# Boston Medical Center (BMC) OBOT in General Internal Medicine

❖ 5/2003 – Began OBOT

❖ 7/2010

- 425 patients (3-6 admissions per week)
- 9 physicians
  - 1 medical director
  - 3 ABAM certified
  - Part-time clinical practices:  
on average, 3 sessions/week (range 1-6)
- 3 RNs (3 FTE)
- 1 medical asst (1 FTE)
- 1 program coordinator (1 FTE)
- 1 program director (.4 FTE)



# Boston Medical Center (BMC) OBOT in General Internal Medicine

## ❖ 7/2016

- 7 new admissions per week
- 17 waived physicians
  - 12 ABAM certified
  - Part-time clinical practices:  
on average, 3 sessions/week (range 1-6)
- RNs (5.5 FTE)
- medical asst (1 FTE)
- program coordinator (.2 FTE)
- program director (.1 FTE)

# BMC OBOT became known as Massachusetts Model of OBOT

- ❖ Program Coordinator intake call
  - Screens the patient over the telephone
  - OBOT Team reviews the case for appropriateness
- ❖ NCM and physician assessments
  - Nurse does initial intake visit and collects data
  - Physician: PE, and assesses appropriateness, DSM criteria of opioid use disorder
- ❖ NCM supervised induction (on-site) and managed stabilization (on- and off-site (by phone))
  - Follows protocol with patient self administering medication per prescription



# Nurse Care Managers (NCM)

- ❖ Registered nurses, completed 1 day buprenorphine training
- ❖ Performed patient education and clinical care by following treatment protocols (e.g., UDT, pill counts, periop mgnt)
- ❖ Ensured compliance with federal laws
- ❖ Coordinated care with OBOT physicians
- ❖ Collaborated care with pharmacists (refills management) and off-site counseling services
- ❖ Drop-in hours for urgent care issues
- ❖ Managed all insurance issues (e.g., prior authorizations)
- ❖ On average each NCM saw 75 patients/wk

# Massachusetts Model of OBOT

- ❖ Maintenance treatment patient in care (at least 6 months)
  - NCM visits weekly for 4-6 wks, then q2 wks, then q1-3 months and as needed
  - **OBOT physician visits at least every 4 months**
- ❖ Medically supervised withdrawal considered based on stability if the patient requested to taper
- ❖ Transferred to methadone if continued illicit drug use or need for more structured care
- ❖ Discharged for disruptive behavior

# Preadmission Factors Associated with Treatment Success

Characteristic	OR (95% CI)
Older age	<b>1.40</b> (1.09-1.80)
Employed	<b>2.24</b> (1.33-3.77)
Illicit buprenorphine use	<b>3.04</b> (1.32-7.00)
African American	<b>0.50</b> (0.26-0.99)
Hispanic	<b>0.45</b> (0.22-0.93)

# Urine Drug Tests (UDT)

Month	3	6	9	12
<b>Illicit Opioid NEG</b>	95%	94%	93%	95%
<b>Cocaine NEG</b>	95%	96%	95%	98%

## Table 2. Treatment Outcomes at 12 Months of 382 Opioid-Dependent Patients Entering Office-Based Opioid Treatment in Primary Care

Outcome	Patients, No. (%)
Successful treatment	196 (51.3)
Treatment retention	187 (49.0)
Successful taper after 6 months of adherence <sup>a</sup>	9 (2.4)
Unsuccessful treatment	162 (42.4)
Lost to follow-up	113 (29.6)
Nonadherence despite enhanced treatment <sup>a</sup>	46 (12.0)
Administrative discharge due to disruptive behavior	2 (0.5)
Adverse effects of buprenorphine hydrochloride	1 (0.3)
Transfer to methadone hydrochloride treatment program	24 (6.3)

## Table 2. Treatment Outcomes at 12 Months of 382 Opioid-Dependent Patients Entering Office-Based Opioid Treatment in Primary Care

Outcome	Patients, No. (%)
Successful treatment	196 (51.3)
Treatment retention	187 (49.0)
Successful taper after 6 months of adherence <sup>a</sup>	9 (2.4)
Unsuccessful treatment	162 (42.4)
Lost to follow-up	113 (29.6)
Nonadherence despite enhanced treatment <sup>a</sup>	46 (12.0)
Administrative discharge due to disruptive behavior	2 (0.5)
Adverse effects of buprenorphine hydrochloride	1 (0.3)
Transfer to methadone hydrochloride treatment program	24 (6.3)

# Conclusions

- ❖ Patient-level outcomes comparable to physician-centered approaches
- ❖ Allows efficient use of physician time to focus on patient management (e.g., dose adjustments, maintenance vs. taper)
  - Allowed physicians to manage > numbers of patients due to support of NCM
- ❖ Improved access to OBOT and daily management of complex psychosocial needs (e.g., housing, employment, health insurance)



# MA Department of Public Health Bureau of Substance Abuse Services Released two programs: In Response to Unmet Need

- ❖ Funding for a Nurse Care Manager Model in Community Health Centers (CHC)
  - Required CHC to partner with addictions counseling service providers
- ❖ Funding for training and technical assistance to the CHC OBOT programs

# Program Funding

- ❖ \$270,000 per year for Technical Assistance: training, booster sessions, quarterly state educational sessions, conference calls, site visits, support staff and admin assistance, support to statewide providers in nonprofits, accountability of grant deliverables.
- ❖ \$100,000 per CHC for Nurse Care Manager
  - 1 full time RN
  - 1:100 staff to patient ratio
    - Rolling admission of new patients each week to reach 100
  - 1:125 with addition of Medical Assistant in year 4 of the grant

# TA Support




- ❖ Nursing training and ongoing support
  - Phone, email, site visits, chart reviews
  - Quarterly statewide NCM meetings:
    - addiction education, support, networking
- ❖ Site support:
  - Education all providers
    - Trainings: addiction, buprenorphine, stigma, management, set up
  - Support practice: MD and nursing issues
  - Care for or triage patients to other sites due to closures, staff changes, emergency issues
  - DEA Support: Education and preparation, support at visits
  - Waiver assistance, insurance support, coverage, carrier issues

# UMass Study Findings in Massachusetts

- ❖ Studied 5,600 Mass Health Clients prescribed buprenorphine and methadone (2003-2007)
- ❖ Overall Mass Health expenditures lower than for those with no treatment
- ❖ Clients on Medications had significantly lower rates of relapse, hospitalizations and ED visits: no more costly than other treatments
- ❖ Buprenorphine attracting younger and newer clients to treatment


## Average Hospital Admissions Per OBOT Enrollment



**Notes:**

- Hospital data is only available through 9/30/2012
- Enrollments must have lasted at least 12 months
- Paid amounts are calculated using hospital specific pay to charge ratios


## Average ER Visits Per OBOT Enrollment



**Notes:**

- Hospital data is only available through 9/30/2012
- Enrollments must have lasted at least 12 months
- Paid amounts are calculated using hospital specific pay to charge ratios

## Total ER Expenditures: % Difference From Prior 6 Months



**Notes:**

- Hospital data is only available through 9/30/2012.
- Enrollments must have lasted at least 12 months
- Paid amounts are calculated using hospital specific pay to charge ratios

# OBOT RN

## Nursing Assessment:

- ❖ Intake assessment
  - Review medical hx, treatment hx, pain issues, mental health, current use, and medications
- ❖ Consents/Treatment agreements
  - Program expectations: visits & frequency, UDT, behavior
  - Understanding of medication: opioid, potential for withdrawal
  - Review, sign, copies to patient and review at later date
- ❖ Education
  - On the medication (opioid), administration, storage, safety, responsibilities and treatment plan
- ❖ UDT
- ❖ LFTs, Hepatitis serologies, RPR, CBC, pregnancy test

# OBOT RN Induction Preparation:

## Review the requirements program:

- ❖ Nurse/ Physician Appointments:
  - frequency, times, location
- ❖ Counseling:
  - weekly initially
- ❖ UDT:
  - at visits, call backs
- ❖ Abstinence:
  - from opioids is the goal
- ❖ Insurance verification:
  - prior authorizations, co-pays
- ❖ Safety:
  - medication storage (bank bag)

# OBOT Team

## Patient instructions for induction day:

- ❖ Insurance verification
  - Prior authorizations, co-pays
- ❖ Dispose of paraphernalia, phone numbers, contacts
- ❖ Medication pick up: 2mg/8mg tabs
- ❖ No driving for 24 hours
- ❖ Plan to be at clinic or office for 2-4 hours
- ❖ Bring a support person if possible
- ❖ Discuss potential side effects (e.g. precipitated withdrawal)




# OBOT MD

- ❖ Review of history
  - Mental health, substance use, medical, social
- ❖ Physical Exam
- ❖ Lab and urine review
  - Assess contraindications, toxicology
- ❖ Confirm opioid use disorder diagnosis
  - DSM criteria
- ❖ Confirm appropriate for office treatment
- ❖ Signs the orders and prescription
- ❖ Develop treatment plan with OBOT team

# OBOT RN, MD

## Planning for Induction:

- ❖ Asking patient to show up in withdrawal requires a great deal of TRUST
- ❖ Build a relationship: Support
- ❖ Review with patient ahead of time usage history, withdrawal and make a plan
- ❖ Written materials, ongoing education
- ❖ Emergency and contact numbers



# OBOT RN

## Patient instructions during first dose:

- ❖ Put tablet(s) under tongue: sublingual
- ❖ Don't talk, don't swallow: saliva pools
- ❖ May use mirror, watch the tablet(s) gradually shrink as they dissolve
- ❖ May drink before and after not during

# OBOT RNs

## Initial dose buprenorphine

- ❖ COWs >8-12
- ❖ Objective signs are key to making dx
- ❖ Start with 2-4mg sl
- ❖ Assess 40min-1 hour after dosing
  - Better, worse, or the same
- ❖ Repeat dose of 2mg, assess 1 hour
  - Send home with instructions to call RN

# OBOT RN

## Frequency of Visits:

- ❖ Phone contact daily, or daily visits for first few days or more if needed
- ❖ At least weekly until stabilized (usually 4-6 weeks)
  - dose, UDT, counseling
- ❖ Progress to every two weeks, monthly, random, q3-4 months

# OBOT RN

## Comfort Measures:

- ❖ Taste perversion
- ❖ Headaches
- ❖ Nausea
- ❖ Sweating
- ❖ Insomnia



Consult with OBOT MD if needed

# OBOT RN/MD Prescriptions

- ❖ Early On:
  - Small prescriptions 1 week with refills
  - Increase as patient stabilizes (UDT)
  - 2 week prescriptions with refills
- ❖ At point of stabilization:
  - Monthly visits
  - Monthly prescriptions with refills
- ❖ Keep file of pharmacy contact info

# OBOT RN

## Follow up Visits:

- ❖ Assess dose, frequency, cravings, withdrawal
- ❖ Ongoing education: dosing, side effects, interactions, support.
- ❖ Counseling, self help check in
- ❖ Psychiatric evaluation and follow up as needed
- ❖ Medical issues: vaccines, follow up, treatment HIV, HCV, engage in care
- ❖ Assist with preparing prescriptions
- ❖ Facilitating prior approvals and pharmacy
- ❖ Pregnancy: if pregnant engage in appropriate care
- ❖ Social supports: housing, job, family, friends

# OBOT Team Monitoring

- ❖ UDT
- ❖ Pill counts
- ❖ Pharmacy Check-in
- ❖ Observed Dosing
- ❖ Random call backs
- ❖ Scheduled visits
- ❖ Counseling check in
- ❖ Check in with support/family/parent/partner



# Next Steps

- ❖ Utilizing nurse care manager models to expand treatment to more sites
- ❖ Increase level of education among providers in addiction treatment
  - Nurses, doctors, support staff, and administration
- ❖ Integrate into the medical home model of care
- ❖ Examine and improve retention



**Thank you!**